MedPath

Pyronaridine

Generic Name
Pyronaridine
Drug Type
Small Molecule
Chemical Formula
C29H32ClN5O2
CAS Number
74847-35-1
Unique Ingredient Identifier
TD3P7Q3SG6

Overview

Pyronaridine has been investigated for the treatment of Malaria.

Indication

本品用于治疗脑型、凶险型及耐氯喹虫珠所致的恶性疟,也用于治疗间日疟。

Associated Conditions

  • Acute Falciparum Malaria
  • Acute Malaria caused by plasmodium vivax

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2023/08/03
Phase 2
Completed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2023/01/18
Phase 2
Completed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
2022/07/01
Phase 1
Not yet recruiting
2022/03/22
Phase 2
UNKNOWN
2022/03/18
Phase 1
Completed
Medicines for Malaria Venture
2021/12/16
Phase 1
Completed
Medicines for Malaria Venture
2020/04/30
Phase 3
Terminated
Medicines for Malaria Venture
2019/08/08
Phase 2
Completed
2019/01/24
Phase 2
UNKNOWN
2017/06/28
Phase 4
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Malaridine Phosphate Injection
国药准字H33020031
化学药品
注射剂
3/2/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath